Takeda Announces Third-Quarter FY2023 Results; On-Track Towa

Two New U.S. FDA Approvals in FY2023 Q3: FRUZAQLA for Adults With Previously Treated Metastatic Colorectal Cancer and ADZYNMA for Ultra-Rare Blood Clotting Disorder cTTPStrong Commercial Execution Maximizing Value of Existing Portfolio:ENTYVIO® Pen Launched in U.S. for Ulcerative Colitis; U.S. FDA Approval Decision...

Related Keywords

United States , Japan , Osaka , Christopher Oreilly , Actual Exchange Rate , Constant Exchange Rate , International Financial Reporting Standards , Exchange Commission , Digital Technology , Takeda Pharmaceutical Company Limited , Ultra Rare Blood Clotting Disorder , Commercial Execution Maximizing Value , Existing Portfolio , Pen Launched , Ulcerative Colitis , Disease Filing Expected , Dengue Vaccine Now Launched , Chinafor Refractory Post Transplant , Operating Profit Change , Reflecting Generic Impact , Lower Coronavirus Vaccines Revenue , Increased Investment , Cycle Management Approvals , January Support Forward Momentum , Launch Products , Costa Saroukos , Management Guidance , Free Cash Flow , Annual Report , Score Revenue , Core Operating Profit , Core Net Profit , Net Debt , Free Cash ,